Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Antithymocyte globulin - Sanofi Genzyme

Drug Profile

Antithymocyte globulin - Sanofi Genzyme

Alternative Names: anti-thymocyte globulin; anti-thymocyte globulin (rabbit); Antithymocyte immunoglobulin; ATG; Polyclonal rabbit antithymocyte globulin; Rabbit antithymocyte globulin; Rabbit-ATG; rATG; Thymoglobulin; Thymoglobuline

Latest Information Update: 11 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi pasteur
  • Developer Cedars-Sinai Medical Center; Genzyme Corporation; National Institute of Diabetes and Digestive and Kidney Diseases; Sanofi Genzyme; Sanofi Pasteur; University of Texas M. D. Anderson Cancer Center; Virginia Commonwealth University
  • Class Polyclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Bone marrow transplant rejection; Graft-versus-host disease; Liver transplant rejection; Pancreas transplant rejection; Renal transplant rejection; Transplant rejection
  • Phase II Heart transplant rejection; Myelodysplastic syndromes; Type 1 diabetes mellitus

Most Recent Events

  • 16 Jul 2019 Sanofi Company completes a phase I/II trial in Type-1 diabetes mellitus (Combination therapy) in USA (IV) (NCT01106157)
  • 23 Oct 2018 No development reported - Phase-II for Liver transplant rejection (Combination therapy, Prevention) in USA (IV)
  • 13 Sep 2018 Phase-II clinical trials in Heart transplant rejection (Prevention) in USA (IV) (NCT03292861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top